[1]吴晓红.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对哮喘-慢阻肺重叠综合征患者炎症因子水平及肺功能的影响[J].医学信息,2022,35(20):139-141.[doi:10.3969/j.issn.1006-1959.2022.20.038]
　WU Xiao-hong.Effects of Budesonide Formoterol Fumarate Powder Inhalation Combined with Montelukast Sodium on Inflammatory Factor Levels and Lung Function in Patients with Asthma-chronic Obstructive Pulmonary Overlap Syndrome[J].Journal of Medical Information,2022,35(20):139-141.[doi:10.3969/j.issn.1006-1959.2022.20.038]
点击复制

布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对哮喘-慢阻肺重叠综合征患者炎症因子水平及肺功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年20期
页码:
139-141
栏目:
药物与临床
出版日期:
2022-10-15

文章信息/Info

Title:
Effects of Budesonide Formoterol Fumarate Powder Inhalation Combined with Montelukast Sodium on Inflammatory Factor Levels and Lung Function in Patients with Asthma-chronic Obstructive Pulmonary Overlap Syndrome
文章编号:
1006-1959（2022）20-0139-03
作者:
吴晓红
（余干县人民医院器械科，江西 余干 335199）
Author(s):
WU Xiao-hong
(Department of Instrument,Yugan County People’s Hospital,Yugan 335199,Jiangxi,China)
关键词:
哮喘-慢阻肺重叠综合征; 孟鲁司特钠; 布地奈德福莫特罗粉吸入剂; 炎症因子; 肺功能
Keywords:
Asthma-COPD overlap syndrome; Montelukast sodium; Budesonide formoterol powder inhalation; Inflammatory factors; Lung function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2022.20.038
文献标志码:
A
摘要:
目的 研究布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对哮喘-慢阻肺重叠综合征（ACOS）患者炎症因子水平及肺功能的影响。方法 选取2020年5月-2021年5月余干县人民医院收治的68例ACOS患者，按照随机数字表法分为对照组与观察组，各34例。对照组采用布地奈德福莫特罗粉吸入剂治疗，观察组在其基础上加用孟鲁司特钠治疗，比较两组临床疗效、哮喘症状评分（ACT评分）、慢阻肺症状评分（CAT评分）、血清炎症因子水平[C反应蛋白（CRP）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）]、肺功能[用力肺活量（FVC）、峰值流速（PEF）、第1秒用力呼气量占用力肺活量的百分比（FEV1/FVC%）]。结果 观察组治疗总有效率高于对照组（P＜0.05）；观察组治疗后ACT评分高于对照组，CAT评分低于对照组（P＜0.05）；观察组治疗后CRP、IL-6、TNF-α水平低于对照组，且FVC、PEF、FEV1/FVC高于对照组（P＜0.05）。结论 布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗ACOS的效果确切，可改善患者的哮喘及慢阻肺症状，下调其炎症反应，同时提高肺功能水平。
Abstract:
Objective To study the effect of budesonide formoterol powder inhalation combined with montelukast sodium on inflammatory factor levels and lung function in patients with asthma-chronic obstructive pulmonary overlap syndrome (ACOS).Methods A total of 68 patients with ACOS admitted to Yugan County People’s Hospital from May 2020 to May 2021 were selected and divided into control group and observation group according to the random number table method, with 34 cases in each group. The control group was treated with budesonide formoterol powder inhalation, and the observation group was treated with montelukast sodium on the basis of the control group. The clinical efficacy, asthma symptom score (ACT score), chronic obstructive pulmonary symptom score (CAT score), serum inflammatory factor levels [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)], lung function [forced vital capacity (FVC), peak expiratory flow (PEF), forced expiratory volume in the first second as a percentage of forced vital capacity (FEV1/FVC%)] were compared between the two groups.Results The effective rate of treatment in the observation group was higher than that in the control group (P<0.05). After treatment, the ACT score of the observation group was higher than that of the control group, and the CAT score was lower than that of the control group (P<0.05). After treatment, the levels of CRP, IL-6 and TNF-α in the observation group were lower than those in the control group, and the indexes of FVC, PEF and FEV1/FVC were higher than those in the control group (P<0.05).Conclusion Budesonide formoterol powder inhalation combined with montelukast sodium is effective in the treatment of ACOS, which can significantly improve the symptoms of asthma and COPD, down-regulate the inflammatory response and improve the level of lung function.

参考文献/References:

[1]Wang YC,Jaakkola MS,Lajunen TK,et al.Asthma-COPD Overlap Syndrome （ACOS） among Subjects with Newly Diagnosed Adult-Onset Asthma[J].Allergy,2018,73(7):1554-1557.[2]常社教.孟鲁司特钠治疗对哮喘-慢阻肺重叠综合征患者肺功能及IL-6、TNF-α水平的影响[J].实用中西医结合临床,2021,21(14):74-75.[3]邱升蓝.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的临床疗效[J].临床合理用药杂志,2021,14(18):24-26.[4]李研,佟飞,米香.布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗ACOS的疗效及其对患者血清hs-CRP、EOS的影响[J].海南医学,2017,28(18):2997-3000.[5]王丹阳.孟鲁司特钠联合布地奈德、福莫特罗治疗哮喘——慢阻肺重叠征的临床效果[J].新疆医学,2020,50(10):1033-1037.[6]孙永昌.哮喘-慢阻肺重叠综合征指南解读[J].中国呼吸与危重监护杂志,2014,13(4):325-329.[7]周珍,蔡坤松.布地奈德福莫特罗粉吸入剂结合孟鲁司特钠治疗哮喘-慢阻肺重叠综合征患者的效果及安全性分析[J].中外医学研究,2020,18(8):41-43.[8]朱念,金文静,王志华.孟鲁司特钠辅助治疗哮喘-慢性阻塞性肺疾病重叠患者的临床疗效[J].实用心脑肺血管病杂志,2019,27(4):95-98.[9]林诗烽,陈黎仙,林国勇,等.孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的临床效果分析[J].中外医学研究,2020,18(1):152-154.[10]张勇,韩兆勇.孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床研究[J].中国临床药理学杂志,2020,36(7):744-746.[11]冯二香.孟鲁司特钠联合舒利迭治疗哮喘-慢阻肺重叠综合征的临床效果观察[J].河南医学研究,2018,27(23):4308-4309.[12]李彦芳,李震.孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的临床效果分析[J].内蒙古医学杂志,2018,50(11):1345-1346.[13]洪敏,洪芳.孟鲁司特钠对哮喘-慢阻肺重叠综合征患者呼吸困难指数的影响[J].全科医学临床与教育,2017,15(4):449-451.[14]马福莉.孟鲁司特钠辅助常规治疗哮喘-慢阻肺重叠综合征的可行性分析[J].齐齐哈尔医学院学报,2018,39(18):2126-2127.[15]张华根,曾伟坚,彭贵霞,等.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在哮喘-慢阻肺重叠综合征患者治疗中的应用研究[J].实用药物与临床,2018,21(7):811-814.[16]刘宇智,金宁,王海斌.孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的疗效分析[J].临床肺科杂志,2017,22(7):1293-1296.[17]Chen X,Zhang X,Pan J.Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms[J].Medical Science Monitor,2019,25:1886-1893.

相似文献/References:

[1]李波.孟鲁司特钠联合酮替芬治疗小儿支气管炎的临床效果分析[J].医学信息,2018,31(02):130.[doi:10.3969/j.issn.1006-1959.2018.02.048]
　LI Bo.Clinical Analysis of Montelukast Sodium Combined With Ketotifen in the Treatment of Bronchitis in Children[J].Journal of Medical Information,2018,31(20):130.[doi:10.3969/j.issn.1006-1959.2018.02.048]
[2]尹静华.孟鲁司特钠治疗小儿哮喘的临床有效性分析[J].医学信息,2018,31(09):138.[doi:10.3969/j.issn.1006-1959.2018.09.043]
　YIN Jing-hua.Clinical Efficacy of Montelukast Sodium in Children with Asthma[J].Journal of Medical Information,2018,31(20):138.[doi:10.3969/j.issn.1006-1959.2018.09.043]
[3]张明荣.孟鲁司特钠联合布地奈德治疗小儿哮喘的临床疗效分析[J].医学信息,2018,31(13):131.[doi:10.3969/j.issn.1006-1959.2018.13.038]
　ZHANG Ming-rong.Clinical Analysis of Montelukast Sodium Combined with Budesonide in the Treatment of Childhood Asthma[J].Journal of Medical Information,2018,31(20):131.[doi:10.3969/j.issn.1006-1959.2018.13.038]
[4]张 健.孟鲁司特钠联合氯雷他定治疗小儿过敏性紫癜的疗效及对炎性因子、免疫球蛋白水平的影响[J].医学信息,2022,35(15):107.[doi:10.3969/j.issn.1006-1959.2022.15.024]
　ZHANG Jian.Effect of Montelukast Sodium Combined with Loratadine in the Treatment of Anaphylactoid Purpura in Children and its Effect on Inflammatory Factors and Immunoglobulin Levels[J].Journal of Medical Information,2022,35(20):107.[doi:10.3969/j.issn.1006-1959.2022.15.024]
[5]韦春峥,莫 彬,莫善圆,等.孟鲁司特钠联合布地奈德治疗儿童支气管哮喘合并变应性鼻炎的临床效果[J].医学信息,2019,32(20):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
　WEI Chun-zheng,MO Bin,MO Shan-yuan,et al.Clinical Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchial Asthma Complicated with Allergic Rhinitis[J].Journal of Medical Information,2019,32(20):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
[6]甘 瀛.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效[J].医学信息,2019,32(12):150.[doi:10.3969/j.issn.1006-1959.2019.12.049]
　GAN Ying.Efficacy of Montelukast Sodium Combined with Budesonide in the Treatment of Cough Variant Asthma in Children[J].Journal of Medical Information,2019,32(20):150.[doi:10.3969/j.issn.1006-1959.2019.12.049]
[7]陈小军.布地奈德联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的疗效[J].医学信息,2020,33(06):154.[doi:10.3969/j.issn.1006-1959.2020.06.051]
　CHEN Xiao-jun.Efficacy of Budesonide Combined with Tiotropium Bromide in the Treatment of Asthma-COPD Overlap Syndrome[J].Journal of Medical Information,2020,33(20):154.[doi:10.3969/j.issn.1006-1959.2020.06.051]
[8]凌春艳.布地奈德气雾剂联合孟鲁司特钠治疗老年咳嗽变异性哮喘的疗效[J].医学信息,2020,33(07):144.[doi:10.3969/j.issn.1006-1959.2020.07.046]
　LING Chun-yan.Efficacy of Budesonide Aerosol Combined with Montelukast Sodium in the Treatment of Elderly Cough Variant Asthma[J].Journal of Medical Information,2020,33(20):144.[doi:10.3969/j.issn.1006-1959.2020.07.046]
[9]安 静.孟鲁司特钠联合特布他林对哮喘患儿呼吸功能的影响[J].医学信息,2022,35(21):128.[doi:10.3969/j.issn.1006-1959.2022.21.033]
　AN Jing.Effect of Montelukast Sodium Combined with Terbutaline on Respiratory Function in Children with Asthma[J].Journal of Medical Information,2022,35(20):128.[doi:10.3969/j.issn.1006-1959.2022.21.033]
[10]牛春生.孟鲁司特钠联合糠酸莫米松治疗过敏性鼻炎致轻中度腺样体肥大的效果[J].医学信息,2020,33(22):153.[doi:10.3969/j.issn.1006-1959.2020.22.044]
　NIU Chun-sheng.The Effect of Montelukast Sodium Combined with Mometasone Furoate in the Treatment of Mild to Moderate Adenoid Hypertrophy Caused by Allergic Rhinitis[J].Journal of Medical Information,2020,33(20):153.[doi:10.3969/j.issn.1006-1959.2020.22.044]

更新日期/Last Update: 1900-01-01